On-site automated NGS using circulating tumor DNA enabled comprehensive genomic testing in ~27 hours, substantially shortening the interval between diagnosis and potential targeted-therapy selection.
Diagnosis requires a tissue biopsy for histopathologic and immunohistochemistry evaluation. Testing for alterations using non-small cell lung cancer (NSCLC) tumor tissue requires acquisition of a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results